Telangiectasia, Hereditary Hemorrhagic Clinical Trial
Official title:
The ELLIPSE Study: A Phase-1 Study Evaluating the Tolerance of Bevacizumab Nasal Spray to Treat Epistaxis in Hereditary Hemorrhagic Telangiectasia.
Antiangiogenic drugs, such as bevacizumab, are a new treatment strategy in Hereditary Hemorrhagic Telangiectasia (HHT). Its systemic administration in patients with HHT improves liver damage-related symptoms and epistaxis (cases reported and on-going study-ClinicalTrials.gov Identifier #NCT00843440-). To limit the systemic adverse effects of bevacizumab and to ease administration, a local administration seems suitable. A clinical case recently showed the benefits of bevacizumab nasal spray in these patients. Its results were confirmed in a characterization study on bevacizumab transport through porcine nasal mucosa (in press). It seems necessary to assess the tolerance and efficacy of bevacizumab nasal spray in humans for the treatment of epistaxis in HHT with a prospective phase 1 study. The primary objective of the study is to evaluate the tolerance of increasing doses of bevacizumab administered as a nasal spray in patients with HHT-related epistaxis. This phase-1, randomized, double-blind, placebo-controlled, monocentric study is to be carried out sequentially (dose escalation) on 5 groups of 8 patients. Each group is made up of 6 verum and 2 placebos.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03227263 -
BABH Study: Efficacy and Safety of Bevacizumab on Severe Bleedings Associated With Hemorrhagic Hereditary Telangiectasia (HHT).
|
Phase 3 | |
| Completed |
NCT00733655 -
Study of Histological Samples From Patients With Hereditary Haemorrhagic Telangiectasia
|
||
| Completed |
NCT00355108 -
ATERO : A Randomised Study With Tranexamic Acid in Epistaxis of Rendu Osler Syndrome
|
Phase 3 | |
| Completed |
NCT03910244 -
Pomalidomide for the Treatment of Bleeding in HHT
|
Phase 2 | |
| Completed |
NCT04108052 -
Diagnostic Value of Ultra-low Dose Thoracic Scanner for the Pulmonary Arteriovenous Malformation Detection in HHT Patient
|
N/A | |
| Recruiting |
NCT04976036 -
Efficacy of Nintedanib for Treatment of Epistaxis in Hereditary Hemorrhagic Telangiectasia (HHT) Patients
|
Phase 2 | |
| Completed |
NCT00684879 -
Screening Behavior in Adults With Hereditary Hemorrhagic Telangiectasia
|
||
| Completed |
NCT00004648 -
Studies of Hereditary Hemorrhagic Telangiectasia
|
N/A | |
| Completed |
NCT00230672 -
Investigation of Plasma Proteins in Patients With Hereditary Haemorrhagic Telangiectasia and PAVMs
|
||
| Completed |
NCT03954782 -
Efficacy of Nintedanib Per os as a Treatment for Epistaxis in HHT Disease.
|
Phase 2 | |
| Completed |
NCT02484716 -
Efficacy of a Timolol Nasal Spray as a Treatment for Epistaxis in Hereditary Hemorrhagic Telangiectasia (HHT) - (TEMPO)
|
Phase 2 | |
| Recruiting |
NCT00230685 -
Case Notes Review on Patients With Hereditary Haemorrhagic Telangiectasia
|
||
| Terminated |
NCT02204371 -
Evaluation of Pazopanib on Bleeding in Subjects With Hereditary Haemorrhagic Telangiectasia
|
Phase 2 | |
| Recruiting |
NCT00230620 -
Molecular Studies on Hereditary Haemorrhagic Telangiectasia Families
|
||
| Recruiting |
NCT02157987 -
Treatment of Hereditary Hemorrhagic Telangiectasia of the Nasal Mucosa by Intranasal Bevacizumab : Search for Effective Dose
|
Phase 1/Phase 2 | |
| Completed |
NCT01408030 -
North American Study of Epistaxis in Hereditary Hemorrhagic Telangiectasia (HHT)
|
Phase 2 | |
| Completed |
NCT00230659 -
Investigation of Coagulation Parameters in Hereditary Haemorrhagic Telangiectasia
|
||
| Withdrawn |
NCT00733629 -
Study of Endothelial Cells in Patients With Hereditary Haemorrhagic Telangiectasia
|
||
| Active, not recruiting |
NCT00230633 -
Studies of White Blood Cells Derived From HHT Patients
|
||
| Recruiting |
NCT05933330 -
Hereditary Hemorrhagic Telangiectasia and Neurovascular Manifestations, in the Danish HHT Database
|